RxDoctor Payments Data

Nicole Williams, MD

Medical Oncology · Columbus, OHNPI 1295998979

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,708 of the $14,062 with a category attached, or 83.3%. 11 manufacturers reported payments, led by Gilead at 53.5% of the total. Reporting peaked in 2024 at $11,402 and has fallen 80.1% since, to $2,264 in 2025.

$14,062in general payments, 2019–2025

Across 29 payments — averaging $484.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$8K
  • Novartis$2K
  • Genentech USA, Inc.$2K
  • Daiichi Sankyo Inc.$2K
  • AbbVie$209
  • Stemline Therapeutics Inc.$144
  • plus $428 from 5 others
$2,447,397in research payments, 2019–2025

Across 109 payments — averaging $22,453 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2.2M
  • Daiichi Sankyo Inc.$89K
  • Eli Lilly$75K
  • AstraZeneca$36K
  • Hoffmann-la Roche Limited$28K
  • Jazz Pharmaceuticals Inc.$22K
  • plus $15K from 1 others

What the payments were for

  • Consulting fees$11,70883%
  • Travel & lodging$1,34110%
  • Food & beverage$1,0017%
  • Education$120%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,062 in reported general payments places this provider in the 75th percentile of 157 medical oncology providers in Ohio.

See all medical oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$60,452
Medicare patients
239
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate59$785,085
IbrancePalbociclib47$748,281
TukysaTucatinib28$567,749
VerzenioAbemaciclib18$257,227
TruqapCapivasertib12$256,010
Anastrozole315$4,964
Exemestane27$3,683
Tamoxifen Citrate38$1,299
Letrozole36$664
Prochlorperazine Maleate27$301
Olanzapine11$247
Pantoprazole Sodium12$69
Gabapentin12$33
Alendronate Sodium11$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$2,100$785,08559 claims
PfizerIbrance$124$748,28147 claims
AstraZenecaTruqap$103$256,01012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 157 medical oncology providers in Ohio.

Other medical oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →